Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition).
10.1007/s11684-021-0891-0
- Author:
Suning CHEN
1
;
Weili ZHAO
2
;
Jianyong LI
3
;
Depei WU
4
Author Information
1. National Clinical Research Center for Hematologic Diseases, Suzhou, 215006, China.
2. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
3. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. lijianyonglm@126.com.
4. National Clinical Research Center for Hematologic Diseases, Suzhou, 215006, China. wudepei@suda.edu.cn.
- Collective Name:Lymphoid Disease Group, Chinese Society of Hematology, Chinese Medical Association
- Publication Type:Journal Article
- Keywords:
B-cell lymphoma;
COVID-19 pandemic;
immunotherapy;
oral drug;
targeted therapy
- MeSH:
Humans;
Consensus;
Lymphoma, B-Cell/drug therapy*;
China
- From:
Frontiers of Medicine
2022;16(5):815-826
- CountryChina
- Language:English
-
Abstract:
Oral drugs such as ibrutinib play an important role in the treatment of mature B-cell lymphoma (BCL) due to their reliable efficacy, manageable safety, high accessibility, and convenience for use. Still, no guidelines or consensus focusing on oral drug therapies for BCL is available. To provide a reference of oral agent-based treatment for mature BCL, a panel of experts from the Lymphocyte Disease Group, Chinese Society of Hematology, Chinese Medical Association conducted an extensive discussion and reached a consensus on oral drugs for Chinese BCL patients on the basis of the current application status of oral drugs in China, combined with the latest authoritative guidelines in the world and current research reports. This consensus reviewed the application of oral drugs in the treatment of BCL and the latest research and provided appropriate recommendations on the use of oral drugs for indolent or aggressive BCL patients. With the deepening of research and the development of standardized clinical applications, oral medications will bring better treatment to BCL patients, enabling more patients to benefit from them.
